SCHEMBL20047063

SCHEMBL20047063

[N-]=[N+]=NCCOCCOCCOCCn1cc(C(=O)O)nn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGMT P16455 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP13 P45452 1/20 0.43
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42
OPRK1 P41145 1/20 0.42
DPP4 P27487 1/20 0.37
FSHR P23945 2/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
KDM6B O15054 1/20 0.34
KDM5C P41229 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34
KDM3A Q9Y4C1 1/20 0.34
FABP7 O15540 1/20 0.34
LHCGR P22888 1/20 0.33
TTR P02766 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21669657 0.86 MMP2 (0.47) MGMTMMP2MMP9MMP8MMP13
SCHEMBL15905756 0.80 OPRM1 (0.40) MGMTMMP2MMP9MMP8MMP13
SCHEMBL20047100 0.80 DPP4 (0.46) DPP4KDM6BKDM5CKDM2AKDM3A
SCHEMBL20046972 0.80 FABP7 (0.41) DPP4DRD2KDM6BKDM5CKDM2A
SCHEMBL20046973 0.79 MMP2 (0.47) MGMTMMP2MMP9MMP8MMP13
SCHEMBL18858993 0.79 MGMT (0.47) MGMTMMP2MMP9MMP8MMP13
SCHEMBL24569987 0.78 MGMT (0.44) MGMTMMP2MMP9MMP8MMP13
SCHEMBL27017059 0.77 MGMT (0.45) MGMTMMP2MMP9MMP8MMP13
SCHEMBL16899887 0.74 MMP2 (0.44) MGMTMMP2MMP9MMP8MMP13
SCHEMBL16899922 0.74 MMP2 (0.44) MGMTMMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109677-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS INC (US) 2026-04-23 US disclosed
US-12522571-B2 Compounds, devices, and uses thereof SIGILON THERAPEUTICS, INC. (US) 2026-01-13 US disclosed
US-20240279187-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS, INC. 2024-08-22 US disclosed
US-11945786-B2 Compounds, devices, and uses thereof SIGILON THERAPEUTICS, INC. (US) 2024-04-02 US disclosed
US-20200039943-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS, INC. 2020-02-06 US disclosed
US-20200039943-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS, INC. 2020-02-06 US disclosed
WO-2018067615-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS, INC. (US) 2018-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039943-A1 COMPOUNDS, DEVICES, AND USES THEREOF SLC10A1, SLCO1B3, SLC5A1 MGMT 1054/4885MMP2 2769/4885MMP9 1131/4885
US-11945786-B2 Compounds, devices, and uses thereof SLC10A1, SLCO1B3, SLC5A1 MGMT 1054/4885MMP2 2769/4885MMP9 1131/4885
US-20240279187-A1 COMPOUNDS, DEVICES, AND USES THEREOF SLC10A1, SLCO1B3, SLC5A1 MGMT 1054/4885MMP2 2769/4885MMP9 1131/4885
US-20260109677-A1 COMPOUNDS, DEVICES, AND USES THEREOF NR3C2, AGTR1, CHRM1 MGMT 1929/4885MMP2 3702/4885MMP9 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.